George Farmer
Stock Analyst at Scotiabank
(1.89)
# 2,967
Out of 4,826 analysts
72
Total ratings
33.33%
Success rate
-6.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $3.43 | +249.85% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $6.85 | +31.39% | 4 | Apr 10, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Sector Outperform | $3.15 → $1.4 | $0.30 | +365.74% | 2 | Mar 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $29.79 | +37.63% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $20.31 | +156.09% | 4 | Feb 27, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $78 → $80 | $62.06 | +28.91% | 8 | Feb 20, 2025 | |
| BIIB Biogen | Maintains: Sector Outperform | $244 → $224 | $121.80 | +83.91% | 3 | Feb 13, 2025 | |
| VKTX Viking Therapeutics | Initiates: Sector Outperform | $102 | $29.49 | +245.88% | 1 | Feb 13, 2025 | |
| SAGE Sage Therapeutics | Maintains: Sector Outperform | $14 → $12 | $7.17 | +67.36% | 5 | Feb 12, 2025 | |
| INMB INmune Bio | Maintains: Sector Outperform | $22 → $23 | $7.57 | +204.03% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $16 | $13.57 | +17.91% | 3 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $6.73 | +48.70% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $656.65 | +8.89% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $5.91 | +289.17% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $2.00 | +902.51% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $21 → $41 | $2.00 | +1,950.00% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $33.40 | +127.54% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $2.87 | +352.96% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $66 | $64.65 | +2.09% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $27.84 | +291.52% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $62.11 | +40.07% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $1.62 | +1,937.04% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.13 | +3,455.56% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $39.84 | -32.23% | 3 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $89 → $75 | $101.86 | -26.37% | 3 | Apr 29, 2020 |
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.43
Upside: +249.85%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $6.85
Upside: +31.39%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Sector Outperform
Price Target: $3.15 → $1.4
Current: $0.30
Upside: +365.74%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $29.79
Upside: +37.63%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $20.31
Upside: +156.09%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $62.06
Upside: +28.91%
Biogen
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $121.80
Upside: +83.91%
Viking Therapeutics
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $29.49
Upside: +245.88%
Sage Therapeutics
Feb 12, 2025
Maintains: Sector Outperform
Price Target: $14 → $12
Current: $7.17
Upside: +67.36%
INmune Bio
Feb 11, 2025
Maintains: Sector Outperform
Price Target: $22 → $23
Current: $7.57
Upside: +204.03%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $16
Current: $13.57
Upside: +17.91%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $6.73
Upside: +48.70%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $656.65
Upside: +8.89%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $5.91
Upside: +289.17%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $2.00
Upside: +902.51%
Sep 27, 2024
Maintains: Sector Outperform
Price Target: $21 → $41
Current: $2.00
Upside: +1,950.00%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $33.40
Upside: +127.54%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $2.87
Upside: +352.96%
Dec 19, 2023
Initiates: Sector Outperform
Price Target: $66
Current: $64.65
Upside: +2.09%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $27.84
Upside: +291.52%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $62.11
Upside: +40.07%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $1.62
Upside: +1,937.04%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $1.13
Upside: +3,455.56%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $39.84
Upside: -32.23%
Apr 29, 2020
Maintains: Outperform
Price Target: $89 → $75
Current: $101.86
Upside: -26.37%